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Abstract
The Gram-positive bacterium Staphylococcus aureus, similar to other pathogens, binds human complement regulators
Factor H and Factor H related protein 1 (FHR-1) from human serum. Here we identify the secreted protein Sbi
(Staphylococcus aureus binder of IgG) as a ligand that interacts with Factor H by a—to our knowledge—new type of
interaction. Factor H binds to Sbi in combination with C3b or C3d, and forms tripartite Sbi:C3:Factor H complexes.
Apparently, the type of C3 influences the stability of the complex; surface plasmon resonance studies revealed a higher
stability of C3d complexed to Sbi, as compared to C3b or C3. As part of this tripartite complex, Factor H is functionally active
and displays complement regulatory activity. Sbi, by recruiting Factor H and C3b, acts as a potent complement inhibitor,
and inhibits alternative pathway-mediated lyses of rabbit erythrocytes by human serum and sera of other species. Thus, Sbi
is a multifunctional bacterial protein, which binds host complement components Factor H and C3 as well as IgG and b2-
glycoprotein I and interferes with innate immune recognition.
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Introduction
In order to establish an infection pathogens have developed
multiple mechanisms to avoid immune recognition and to escape
host immune attack [1,2]. Complement, which mediates a
powerful immediate innate immune defense of vertebrate hosts,
is activated, within seconds upon entry of a foreign invader [1,2].
Activation of the complement system occurs through three
pathways, the alternative, the classical, or the lectin binding
pathway. The activated system cleaves the central complement
protein C3 into the fragments C3a and C3b, and deposits C3b
onto the surface of a microbe, which normally results in
opsonization and elimination of the microbe by phagocytosis.
This surface deposited C3b initiates further activation of the
complement cascade and results ultimately in the formation of the
membrane attack complex (MAC), which forms a pore in the
membrane and destroys the microbe by complement-mediated
lyses. However for Gram positive bacteria MAC mediated lyses
seems of minor significance. The cleavage products C3a and C5a
serve as potent anaphylatoxins, which attract immune effector cells
to the site of infection. Non-pathogenic microbes are effectively
killed and eliminated by the complement system [3].
In order to restrict complement activation to the surface of an
invading microbe host cells are protected from complement attack
by membrane bound and soluble regulators. Factor H is the major
fluid-phase complement regulator that controls alternative path-
way activation at the level of C3. The 150-kDa Factor H protein is
exclusively composed of 20 structural repetitive protein domains,
termed short consensus repeats (SCR) [4]. Factor H is a member
of a protein family, that includes the Factor H like protein 1 (FHL-
1), encoded by an alternatively spliced transcript of the Factor H
gene, and five Factor H related proteins (FHRs) that are encoded
by separate genes [5]. Factor H controls complement activation by
acting as a cofactor for the serine protease Factor I, which cleaves
surface-bound C3b into iC3b. In addition, by competing with
Factor B for C3b binding Factor H accelerates the decay of the
alternative pathway C3 convertase. Thus, Factor H blocks C3b
deposition and amplification of the complement cascade on the
cell surface [5,6].
In order to survive and to establish an infection, pathogens need
to inhibit the host complement attack and apparently utilize
diverse escape mechanisms. Several pathogens acquire host fluid-
phase complement regulators, like Factor H, FHL-1, FHR-1 and
C4b-binding protein (C4BP) from host plasma and body fluids.
Bound to the surface of a pathogen, these host regulators retain
complement regulatory functions, and inhibit complement activa-
tion. Therefore, acquisition of host regulators masks the
pathogenic surface, which results in survival of the pathogen [7,8].
This common strategy of complement evasion has been
identified for multiple pathogens, including Gram-positive and
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Gram-negative bacteria, human pathogenic fungi, parasites and
viruses and several of the corresponding surface proteins were
identified [1]. The vast majority of these pathogenic surface
proteins bind additional host plasma proteins and display multiple
functions. The M protein of Streptococcus pyogenes binds the
complement regulators Factor H, FHL-1 and C4BP as well as other
plasma proteins, i.e. plasminogen, fibronectin, thrombin, fibrinogen,
IgA, IgG and kininogen [1,9–14]. The Candida albicans surface
protein Glyceratphosphat-Mutase 1 (Gpm1) binds Factor H, FHL-1
and plasminogen [15]. In addition, Complement Regulator
Acquiring Surface Protein 1 (CRASP-1) of Borrelia hermsii and Tuf
of P. aeruginosa, bind Factor H, FHR-1 and plasminogen [16,17]. The
additional Factor H binding pathogenic surface proteins e.g.
CRASP1 of Borrelia burgdorferei, PspC of S. pneumoniae and porin
protein 1A of Neisseria gonorrhoeae are candidates for combined Factor
H and plasminogen binding [18–20]. These pathogenic surface
proteins display multiple functions and interfere with the comple-
ment regulation and coagulation. Thus, multiple or potentially all
pathogens acquire soluble host factors and utilize these proteins for
immune evasion [1].
S. aureus is a major human pathogen responsible for hospital-
and community-acquired infection. The Gram-positive bacterium
permanently colonizes the human skin and mucous membranes of
approximately 20% of the population [21]. Once the pathogen has
crossed host immune barriers S. aureus can cause superficial skin
infection, toxin-mediated diseases or serious invasive infections
depending on the interaction of the pathogen’s virulence factors
and the defense mechanisms of the host [22]. The pathogen
utilizes complex strategies to survive and disseminate within the
host and expresses several virulence factors to block both innate
and adaptive immune response [23].
S. aureus utilizes several proteins to control and evade the host
complement attack. The cell wall-anchored protein A (SpA) binds
the Fc region of IgG [24]. S. aureus expresses the zymogen
staphylokinase, that cleaves human plasminogen into active
plasmin, which in turn cleaves IgG. In both cases recognition of
the pathogen by C1q, the initial component of the classical
complement activation pathway, is inhibited [25,26]. Sbi is an
additional staphylococcal IgG-binding protein that similar to SpA
interacts with the Fc part of IgG [27]. Furthermore, Sbi binds b2-
glycoprotein I, which is also termed apolipoprotein H [28].
Recently, additional effector molecules of S. aureus are identified,
that directly interfere with complement activation at the level of
C3. The extracellular fibrinogen-binding protein (Efb), the Efb
homologous protein (Ehp), and the extracellular complement-
binding protein (Ecb), bind C3 and C3d, prevent further
activation of C3b and consequently block the activity of C3b-
containing convertases [29,30,31,32,33]. The staphylococcal
complement inhibitor (SCIN) acts on surface-bound C3 con-
vertases, C3bBb and C4b2a, by stabilizing these complexes,
thereby reducing the enzymatic activity [34,35].
Here we show binding of Factor H and FHR-1 to the surface of
intact S. aureus and in addition identify the secreted staphylococcal
Sbi protein as a Factor H binding protein. Native Factor H from
human serum binds to Sbi, and this binding is mediated by a second
serum factor, which was identified as C3. Factor H binding is
increased in the presence of C3b or C3d suggesting formation of a
tripartite complex. This complex blocks activation of the alternative
complement pathway. The Factor H binding site of Sbi which was
located to domains III and IV is distinct from the IgG binding sites
which are contained in the N-terminal domains I and II [28]. Here,
we demonstrate a novel mechanism for Factor H binding by Sbi. Sbi
forms a tripartite complex with Factor H and C3b or C3d and this
complex interferes with complement activation.
Results
Factor H binds to the surface of S. aureus
In order to analyze binding of host complement regulators to S.
aureus, strain H591 was incubated in human serum. After extensive
washing bound proteins were eluted, separated by SDS-PAGE,
transferred to a membrane and analyzed by Western blotting. This
approach identified three bands of 150, 43 and 37 kDa, which
represent Factor H, FHR-1b and FHR-1a, respectively (Figure 1A,
lane 2). These proteins were absent in the final wash fraction, thus
suggesting specific binding (Figure 1A, lane 1 and lane 2). The
same proteins were also identified in human serum (Figure 1A,
lane 3). When bacteria were incubated with purified Factor H
binding of the purified protein was also detected in the eluted
fraction (Figure 1B, lane 2).
Factor H binds to secreted protein Sbi
In order to characterize the bacterial ligand mediating this
interaction we hypothesized that the staphylococcal Sbi protein
might represent the binding protein. The N-terminal region of Sbi
(i.e. Sbi-E) is composed of four domains and includes the IgG
binding domains I and II, whereas domains III and IV lack
antibody binding properties (Figure 2A and C) ([28], Burman et al.
JBC in press). IgG binding of Sbi-E and Sbi-I was confirmed for
one polyclonal antiserum and two monoclonal antibodies (mABs),
which are directed to Factor H (Figure 2C, columns 1 and 2).
Antibody binding was rather strong and exceeded the reactivity for
the specific ligand Factor H (Figure 2, compare columns 5 and 1).
Factor H binding and localization of the Factor H binding
domains in Sbi
Sbi is an IgG binding protein, therefore Sbi-E and Sbi-I
interaction with additional ligands cannot be studied by standard
ELISA. Consequently we used the previously described combined
ELISA and Western blot approach (CEWA) to study binding of
human serum proteins to Sbi [36]. CEWA, which allows the
Author Summary
Staphylococcus aureus is a Gram-positive bacterium that
can live as a commensal but can also cause severe life
threatening infections in humans. Upon infection the
bacterium is attacked by the host immune system, and in
particular by the complement system which forms the
immediate, first defence line of innate immunity. In order
to survive, S. aureus has developed multiple evasion
strategies and uses several virulence factors to evade
and inactivate the host complement attack. Here we show
that this pathogen binds the host complement regulators
Factor H from human serum with the secreted and surface
exposed Sbi protein, by a—to our knowledge—new type
of interaction. Factor H binds to Sbi in combination with
another host complement protein C3, C3b or C3d, and
forms tripartite Sbi:C3:Factor H complexes. As part of this
tripartite complex, Factor H is functionally active and
inhibits further complement activation. Sbi, by recruiting
Factor H and C3b, acts as a potent complement inhibitor,
and inhibits alternative pathway-mediated lyses of rabbit
erythrocytes by human serum and sera of different species.
Thus, Sbi is a multifunctional bacterial protein, which binds
host complement components Factor H and C3 as well as
IgG and b2-glycoprotein I and interferes with innate
immune recognition.
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identification of Sbi bound serum proteins by size and by reactivity
with specific antisera, revealed that Factor H as well as both FHR-
1a and FHR-1b bind to Sbi-E, comprising domains I–IV
(Figure 3A, lane 1). Both Factor H and FHR-1a/FHR-1b bound
to the deletion constructs Sbi-III/IV and with lower intensity to
Sbi-IV (Figure 3A, lanes 3 and 4). The IgG binding domain Sbi-I
did not bind the host complement regulators (Figure 3A, lane 2).
As described previously Factor H bound to borrelial CRASP-1
and CRASP-5 and FHR-1a/FHR-1b to CRASP-5 (Figure 3A,
lanes 5 and 6) [36].
Having demonstrated binding of Factor H, FHR-1a and FHR-
1b from human serum to Sbi via domains III and IV, we wanted
to confirm this interaction with purified proteins. However
purified Factor H did not bind to Sbi, but did bind to CRASP-1
and CRASP-5 (Figure 3B). These results suggest that binding of
Factor H to Sbi is mediated by an additional serum factor.
Identification of a serum factor that mediates Factor
H:Sbi interaction
In order to identify the additional serum factor that mediates
binding of the host complement regulatory, we hypothesized that
the central complement component C3, which binds to the
staphylococcal inhibitors Efb, Ehp and Ecb [29,30,32] might be
such a mediator. Consequently binding of purified Factor H in the
presence of the complement proteins C3b and C3d was analyzed
by CEWA. When coincubated with either C3b or C3d Factor H
bound to Sbi-E, Sbi-III/IV and Sbi-IV, but not to Sbi-I
(Figure 4A). This binding suggests that Sbi forms a tripartite
complex with Factor H and C3.
Factor H binds to domains III and IV of Sbi, but not to the IgG
binding domain I. The interaction to the non-IgG binding domains
was confirmed by standard ELISA. Purified Factor H together with
C3b or C3d bound to Sbi-III/IV (Figure 4B, columns 1). Binding of
Factor H together with C3b or C3d to Sbi-IV was rather low. In this
assay the binding of Factor H together with C3b/C3d to Sbi-III/IV
was more pronounced as compared to borrelial CRASP-1
(Figure 4B, compare columns 1 and 3). In addition the C3 fragment
responsible for complex formation with Factor H was assayed by
CEWA and ELISA (Figure 4D and 4E). The C3d-containing
fragments C3, C3b and C3d mediate complex formation of Factor
H with Sbi, but not C3a, C3c nor to iC3b. This result reveals a novel
mechanism of capturing host immune regulators, as Sbi binds Factor
H in combination with a second host ligand, namley C3.
Characterization of the Sbi:C3:Factor H tripartite complex
Having identified staphylococcal Sbi as a protein that binds the
host complement components Factor H together with C3b or C3d,
we analyzed C3 binding and tripartite complex formation in more
detail. First binding of the various forms of C3 was analyzed to
immobilized Sbi-E in real time using surface plasmon resonance. C3
showed a strong association and a relative fast dissociation
(Figure 5A: C3). C3b, used at the same molar ratio showed slower
association, but the Sbi:C3b complex was rather stable (Figure 5A:
C3b). In addition C3d, the degradation product of C3, showed a
more pronounced association and also a slow rate of dissociation
(Figure 5A: C3d). This slow dissociation profile of both C3d and C3b
suggests a high stability of the Sbi:C3b and Sbi:C3d complexes.
Based on the apparent stronger association of C3d to Sbi-E, this
interaction was analyzed in more detail. Sbi-E showed a dose-
dependent binding to immobilized C3d when used at a range of
200, 400 and 800 nM (Figure 5B). The same dose-dependent
binding was observed in a reverse setting with immobilized Sbi-E
(data not shown). These results demonstrate that C3, C3b and
C3d bind directly to the staphylococcal Sbi.
In order to further analyze the interaction and complex formation
Sbi-E representing domains I-IV were immobilized and complex
formation was followed in real time. In this setting purified Factor H
bound rather weakly to immobilized Sbi-E, while C3b binding was
stronger (Figure 5C). An increase was observed in the presence of
both Factor H and C3b confirming formation of a tripartite complex
(Figure 5C). Formation of the tripartite complex was also analyzed
with Factor H and C3d (Figure 5D). In this setting binding of C3d
was similar to that of C3b (compare Figure 5D and Figure 5C) and
based on the RLUs the tripartite Sbi:C3d:Factor H complex showed
more pronounced interaction.
Binding and tripartite complex formation was analyzed to
immobilized Sbi-constructs, i.e. Sbi-E, Sbi-I and Sbi-III/IV, to
localize the C3 binding domains in Sbi. C3d did not bind to the
IgG binding domain Sbi-I, but to Sbi-E and also to the construct
Sbi-III/IV (Figure 5E). C3d interaction to Sbi-E and Sbi-III/IV
was comparable, thus confirming the role of domains III and IV
for the contact. Based on the strong interaction of the
Sbi:C3d:Factor H complex to Sbi-E and to Sbi-III/IV
(Figure 5E) it is concluded that the C3/Factor H interaction
region of Sbi is located exclusively in Sbi domains III and IV.
To characterize the formation of Sbi:C3d:Factor H complex
Sbi-E was coupled to an NTA-chip and complex formation was
Figure 1. Adsorption of Factor H and FHR-1 to intact S. aureus.
Cells of S. aureus strain H591 were incubated in human serum (A) or
with purified Factor H (B). After extensive washing, bound proteins
were eluted, separated by SDS-PAGE and analyzed by Western blotting
using polyclonal Factor H antiserum. (A) In the eluted fraction (lane 2)
polyclonal Factor H antiserum reacted with three bands of 150, 43 and
37 kDa representing Factor H, FHR-1b and FHR-1a, respectively. The
same proteins were also identified in human serum (lane 3). (B) Purified
Factor H bound to the bacteria and was detected in the elute fraction
(lane 2). The mobility of the marker proteins is indicated. NHS, normal
human serum.
doi:10.1371/journal.ppat.1000250.g001
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followed upon sequential addition of C3d and Factor H.
Immobilization of Sbi-E was observed (Figure 5F, phase I) and
upon addition of C3d formation of the Sbi:C3d complex was
followed in real time (Figure 5F, phase II). Upon addition of
Factor H, a further association was detected by the increase in the
surface plasmon resonance signals. These results demonstrate that
Factor H binds directly to the Sbi:C3d complex and that Factor H
does not compete with C3b for Sbi-E binding (Figure 5F, phase
III). The observed mass increase at the surface of the sensor chip
during association of Factor H to the Sbi:C3d complex was higher
than that of Factor H to immobilized C3d (data not shown).
Localization of the Sbi binding domains within Factor H
To further characterize this novel type of Factor H acquisition
with C3, we decided to identify the Factor H domains that are
involved in this interaction. Factor H deletion constructs were
immobilized and used in an ELISA experiment. In the presence of
C3b, Sbi-E and Sbi-III/IV, but not to Sbi-I bound to immobilized
Factor H SCRs 19–20 and SCRs 15–20 (Figure 6, columns 5 and
6). In addition Sbi-I did not bind to any Factor H deletion
construct. Thus the Sbi binding site was localized within the C-
terminal surface binding region of Factor H, within SCRs 19–20
and is restricted to Sbi domains three and four.
Factor H fixed in the Sbi:C3b tripartite complex displays
cofactor activity
Factor H bound to pathogenic ligands maintains complement
regulatory activity which relates to complement evasion [1]. It was
therefore of importance to assay if Factor H fixed in this tripartite
complex is functionally active and has complement regulatory
activity. Factor H and C3b were incubated simultaneously with
immobilized Sbi-E or the deletion fragments Sbi-I, Sbi-III/IV and
Sbi-IV. Subsequently, Factor I was added and the mixture was
incubated further. Following this treatment the proteins were eluted,
separated by SDS-PAGE and after transfer to a membrane the C3b
degradation products were identified by Western blotting. Factor H
bound to Sbi-E in the presence of C3b displayed cofactor activity as
indicated by the disappearance of the a’ band and the appearance of
the a’68- and a’43 bands (Figure 7, lane 1). The same degradation
profile of C3b was observed when Factor H was bound to Sbi-III/IV
(Figure 7, lane 3) or to borrelial CRASP-1 (Figure 7, lane 5). In the
absence of Factor H no degradation of C3b was observed (Figure 7,
lanes 7 and 8). These results show that Factor H attached to Sbi in a
tripartite complex maintains complement regulatory activity.
Characterization of the binding mechanism within the
tripartite complex
Tripartite Sbi:C3d:Factor H complexes represent –to our
knowledge- a novel mechanism for Factor H attachment. Factor
H has a C3b/C3d binding region within the C-terminal recognition
region, which also forms the major contact with Sbi. Therefore we
asked whether the tripartite complex is based on a sandwich type
interaction, by which Sbi binds first intact C3, C3b or C3d and then
Factor H. Alternatively a tripartite complexmay be formed, in which
Factor H directly contacts Sbi and C3. Inhibition experiments were
performed to test this hypothesis and to characterize this interaction
Figure 2. Sbi constructs and antibody binding to Sbi. (A) Schematic structure of Sbi and of Sbi deletion constructs used in the experiments.
The IgG binding domains Sbi-I and Sbi-II are shown in white and the non IgG binding, but Factor H, C3 binding domains (domains III and IV) are
shown in black. In addition the position of the signal peptide (SP), the prolin-rich (P) and the tyrosine-rich (Y) regions are indicated. (B) Sbi deletion
constructs expressed in E. coli were purified by nickel chromatography, separated by SDS PAGE and identified by silver staining. Based on mobility of
the marker proteins the molecular mass of the fragments is as follows. Sbi-E 34 kDa; Sbi-I 9.7 kDa; Sbi-III/IV 17 kDa and Sbi-IV 11 kDa. (C) The IgG
binding fragments Sbi-E and Sbi-I mediate unspecific binding of the Factor H:IgG complex. O binding of purified Factor H is detected to the Non-IgG
binding domains Sbi-III/IV and Sbi-IV. Factor H was immobilized and used a positive control. Binding of Factor H to immobilized recombinant
constructs Sbi-E, Sbi-I, Sbi-III/IV and Sbi-IV was identified with polyclonal Factor H antiserum (anti-SCR 1–4) and specific mABs B22 and C18 by ELISA.
doi:10.1371/journal.ppat.1000250.g002
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in more detail. First Factor H and C3b were incubated in the
presence of Factor H antiserum and Factor H binding to
immobilized Sbi was studied. Preincubation of Factor H with the
specific antiserum decreased binding to Sbi-E and blocked binding
to the fragments Sbi-III/IV and Sbi-IV (Figure 8A, lower panel).
The weak binding of antiserum treated Factor H to intact Sbi-E and
to Sbi-I is explained by binding of the Factor H:IgG complex via the
IgG binding site of Sbi located within domain I.
First binding of Factor H to immobilized Sbi-III/IV in the
presence of increasing amounts of C3d was studied. Already 1 ng
of C3d, resulting in a molar Factor H:C3d ratio of 25:1 enhanced
Factor H:Sbi interaction (Figure 8B).
Secondly, Sbi-III/IV was immobilized, C3d was added and Sbi-
III/IV bound C3d was blocked with increasing amounts of specific
C3d antiserum. Subsequently, the binding of Factor H was
analyzed. Factor H binding was not impaired with antisera titers
up to 1:1000, and was reduced but not completely blocked at the
highest titers (1:100 and 1:10) (Figure 8C). This result shows direct
binding of Factor H to Sbi and indicates that the presence of C3d,
Sbi enhances formation of the tripartite complex.
Similarly, Sbi-III/IV was immobilized and a saturating amount
of C3d was bound. In order to block C3d binding sites on the
Factor H protein, Factor H was preincubated with increasing
concentrations of C3d prior to binding. The preincubated Factor
H:C3d complexes were added to the immobilized Sbi:C3d
complexes and after incubation Factor H binding was analyzed.
Again tripartite Sbi:C3d:Factor H complexes were detected and
complex formation was independent of the amount of C3d used
for preincubation (Figure 8D). This result is in agreement with a
direct Factor H:Sbi contact. In summary the inhibition and
blocking experiments reveal that Factor H binds directly to Sbi
and that binding is assisted by C3d.
Sbi is a complement inhibitor
Staphylococcal Sbi forms a tripartite complex with host
complement proteins Factor H and C3. Consequently the
complement inhibitory activity of Sbi was assayed in a standard
hemolysis assay, using human serum and rabbit erythrocytes. In
this assay Sbi-E and also Sbi-III/IV inhibited complement-
mediated lyses of rabbit erythrocytes in a dose-dependent manner.
Complete inhibition was observed at a concentration of 600 ng of
either Sbi-E or Sbi-III/IV (Figure 9A). In contrast, Sbi-I had no
effect (data nor shown) indicating that C3b and Factor H binding
is relevant for complement inhibitory activity. These results
demonstrate that Sbi acts as a potent complement inhibitor.
Hemolysis of rabbit erythrocytes in human serum was dose-
dependent over a range from 5 to 15% and Sbi blocked hemolysis
efficiently at all serum concentrations (Figure 9B).
To analyze the species range of Sbi-E the inhibitory effect of
Sbi-E was tested using sera of different species. Complement
mediated inhibition was observed in human, mouse and guinea
pig sera, and no effect was detected in dog, goat and sheep sera
(Figure 9C). Thus Sbi acts in human serum but also displays a
broader species range.
Sbi is a potent complement inhibitor. Therefore we investigated
the inhibitory effect of Sbi-E in all three complement pathways. Sbi-
E clearly inhibited alternative pathway activity (Figure 9D, column 2
and 3). When all pathways were activated hemolysis was reduced in
a dose-dependent manner, indicating that the alternative pathway,
which was blocked by Sbi-E, is involved and that the classical and
lectin pathway are unaffected (Figure 9D, columns 7 and 8). This
effect was confirmed upon analyzing the impact on the classical and
the lectin pathway. Sbi-E did not inhibit hemolysis of rabbit
erythrocytes when complement was activated via the classical and
the lectin pathway (Figure 9D, columns 12 and 13).
As Sbi inhibits complement we asked whether Sbi protects S.
aureus from phagocytosis mediated killing. S. aureus was incubated
with complement active human serum in presence or absence of
Sbi-E. Subsequently bacteria were harvested and incubated
together with activated phagocytic THP-1 macrophages. At the
indicated times points bacteria were recovered and the survival
rate was quantitated. The presence of Sbi increased bacterial
survival (Figure 9E), thus indicating that the inhibitor Sbi protects
bacteria from opsonisation and phagocytosis.
These results demonstrate that Sbi-E efficiently inhibits the
alternative, complement pathway and aids in bacterial resistance
against complement mediated phagocytosis.
Discussion
The Gram-positive bacterium S. aureus, similar to other human
pathogens binds the complement regulators Factor H and FHR-1
from human serum. We identify the staphylococcal Sbi protein as
a ligand for the two host complement regulators. Apparently Sbi
binds Factor H by a new mechanism, as this human regulator
binds to Sbi together with C3, which likely results in formation of a
Figure 3. Binding of Factor H and FHR-1 to Sbi. (A) CEWA was
used to analyze interaction of host complement regulators with the IgG
binding Sbi protein. Sbi-E, Sbi-I, Sbi-III/IV and Sbi-IV were immobilized
onto the surface of a microtiter plate and human serum was applied.
After extensive washing bound proteins were eluted, separated by SDS-
PAGE and identified by Western blotting based on their mobility and
their reactivity with mAB C18 that is specific for the C-terminal SCR
domain of Factor H and FHR-1. The borrelial Factor H binding CRASP-1,
the Factor H/FHR-1 binding CRASP-5 and BSA were used as controls.
The mobility of the marker proteins is indicated. (B) Purified Factor H
was used in the same assay.
doi:10.1371/journal.ppat.1000250.g003
A Novel Type of Factor H Acquisition by S. aureus
PLoS Pathogens | www.plospathogens.org 5 December 2008 | Volume 4 | Issue 12 | e1000250
tripartite Sbi:C3:Factor H complex. Arranged in this tripartite
complex Factor H is functionally active and displays complement
regulatory activity. Thus Sbi is a potent complement inhibitor, and
inhibits the hemolytic activity of human and rodent serum on
rabbit erythrocytes via the alternative pathway. Thus the
multifunctional bacterial Sbi protein interferes with innate
immune recognition, by acquisition of multiple host proteins in
form of the complement components Factor H, C3 as well as IgG
and b2-glycoprotein I.
Purified Factor H bound to intact bacteria, but dependent on the
assay showed weak or even no binding to Sbi (compare Figure 1,
Figure 3B and Figure 5C,D). This difference in binding suggests that
Figure 4. Binding of Factor H and C3 to Sbi. (A) Sbi-E, Sbi-I, Sbi-III/IV and Sbi-IV, CRASP-1 and CRASP-5 of Borrelia burgdorferi and BSA were
immobilized and incubated with Factor H together with C3b or C3d. After washing bound proteins were eluted from the wells, separated by SDS-
PAGE and analyzed by Western blotting using the mAB C18. In the presence of C3b or C3d Factor H bound to Sbi-E, Sbi-III/IV, Sbi-IV, CRASP-1 and to
CRASP-5. (B) Sbi-III/IV, Sbi-IV, CRASP-1 and BSA were immobilized and binding of Factor H alone, Factor H and C3b, or Factor H and C3d was assayed
by ELISA using polyclonal Factor H antiserum. Again in the presence of C3b or C3d Factor H bound to Sbi-III/IV, to Sbi-IV weakly and to CRASP-1.
Factor H alone did bind to CRASP-1. (C) Western blot showing C3 and its degradation products which were used for the CEWA approach. (D) Binding
of Sbi to C3 and various degradation. Sbi-E was immobilized and the indicated C3 forms were assayed for binding in the presence of Factor H.
Afterward protein were eluted, separated by SDS-Page, transferred to a membrane and C3 fragments were visualized with specific antiserum. C3, C3b
and C3d bound to Sbi-E (lanes 1, 3 and 5); and iC3b, C3c and C3a did not bind (lanes 2, 4 and 7). In addition NHS derived C3 bound to Sbi-E (lane 6).
BSA was used as negative control (lane 8). (E) Sbi-III/IV was immobilized and binding of Factor H in combination with either C3, C3b, C3d, C3a and
C3c, or Factor H alone was measured using polyclonal Factor H antiserum.
doi:10.1371/journal.ppat.1000250.g004
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intact S. aureus bacteria express an additional Factor H binding
surface protein. The identification of this protein is subject to further
studies. The staphylococcal Sbi protein was identified as a ligand for
Factor H. However Factor H binding is enhanced in the presence of
an additional complement protein C3. A tripartite Sbi:C3b:Factor H
complex is formed (Figure 4 and Figure 5).
Figure 5. Analyzing Sbi:C3 interaction by surface plasmon resonance. (A) Sbi-E was immobilized and C3, C3b and C3d were applied in fluid
phase. C3 showed strong association and after removal of the analyte a relative fast dissociation (dash-dotted line). C3b showed a slower association
profile as compared to unprocessed C3, however the complex was rather stable (dotted line). In addition C3d showed a prominent association profile
and the complex was rather stable (dashed line). (B) Dose-dependent interaction of Sbi-E to immobilized C3d. (C) Effect of C3b on Factor H-Sbi
interaction. Sbi-E was immobilized and binding of the single components Factor H or C3b, or of a combination of the two proteins Factor H and C3b
was analyzed. (D) Effect of C3d on Factor H-Sbi interaction. Sbi-E was immobilized and binding of the single components Factor H or C3d, or of a
combination of the two proteins Factor H and C3d was analyzed. As identical concentrations were used the binding profiles can be directly compared
and thus demonstrate stronger interaction of the complex in the presence of C3d as compared to C3b. (E) The various fragments Sbi-E, Sbi-I and Sbi-
III/IV were coupled to the surface of a sensor chip and binding of proteins Factor H alone or C3d alone or in combination was analyzed. C3d bound to
Sbi-E and Sbi-III/IV with comparable intensities, but did not bind to Sbi-I. The Factor H:C3d complex showed stronger binding to Sbi-E and Sbi-III/IV,
but did not bind to Sbi-I. (F) Subsequent association of Sbi-E, C3d and Factor H to an NTA-chip forming a stable Sbi-E:C3d:Factor H complex.
doi:10.1371/journal.ppat.1000250.g005
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The Factor H contact region for Sbi is located within SCRs 19–
20 (Figure 6). Very similar contact domains were identified for
other microbial Factor H binding proteins, e.g. CRASP-1 and
CRASP-2 of B. burgdorferi, Tuf of P. aeruginosa and Gpm1 of C.
albicans [12,14,16,37]. Inhibition experiments showed that poly-
clonal Factor H antiserum blocks Factor H binding to Sbi
(Figure 8A). In the proposed tripartite complex the regulatory
region of Factor H (i.e. SCRs 1–4) is freely accessible as
demonstrated by the Factor I mediated cleavage of C3b (Figure 7).
The staphylococcal Sbi protein is composed of four globular N-
terminal domains connected to a tyrosine-rich C-terminal domain
via a prolin-rich region (Figure 2A) [38]. A recombinant fragment
with domains I–IV (Sbi-E), as well as constructs Sbi-III/IV and
Sbi-IV, but not Sbi-I bound Factor H in combination with C3b or
C3d (Figure 4 and Figure 5), thus localizing the Factor H binding
region to Sbi domains III and IV. As the Factor H/C3b binding
sites in domain III and IV and the IgG binding sites in domain I
and II are separated, the Sbi protein may simultaneously bind
several host proteins.
The binding properties of Sbi are unique, as –to our
knowledge– Sbi is the first bacterial protein identified that forms
such a tripartite complex with Factor H and C3, C3b or C3d. It
will be of interest to demonstrate whether other proteins of
pathogen origin or virulence factors form similar tripartite
complexes. The Sbi:C3 interaction appears rather complex, as
intact C3 and the two processed forms C3b and C3d display
different binding profiles resulting in different stabilities
(Figure 5A). C3d complexed to Sbi showed the highest binding
intensity of binding, and C3b or C3 a lower interaction. In
addition the rate constants of C3d and Sbi-III/IV when assayed
by surface plasmon resonance did not fit a 1:1 langmuir model of
interaction, but rather fit a bivalent analyte model (Figure S2A and
S2B, Figure S3).The proposed bivalent analyte interaction
together with the different binding profiles for the three C3 forms
suggest that C3 undergoes a conformational change upon binding
to Sbi and exposes additional binding epitopes, which affect Sbi
interaction, or that these C3b/C3d binding region(s) is/are
differently accessible to the bacterial Sbi protein.
During complement activation C3 is cleaved, the C3 cleavage
products bind to Sbi, increase Factor H binding and enhance the
stability of the tripartite complex. Such a feed back regulation may
increase the amount of inhibitory host regulators like Factor H at the
site of infection and result in protection of the pathogen from
complement attack and thus improves bacterial survival (Figure 9E).
This inhibition of the alternative pathway by Sbi indicates that
Factor H bound to Sbi affects the C3 convertase. Within the
tripartite complex Factor H displays complement regulatory
activity (Figure 7) and seems responsible for hemolytic activity
(Figure 9A and data not shown). This explains why Sbi domains
Figure 6. Localization of the Sbi binding regions within Factor H. The indicated Factor H deletion constructs were immobilized to the surface
of a microtiter plate and the Sbi deletion constructs together with C3b were added. Binding was assayed by ELISA using polyclonal Factor H
antiserum. SCRs 15–20 and SCRs 19–20 bound to Sbi-E and Sbi-III/IV but not to Sbi-I. The additional Factor H deletion mutants did not bind to Sbi.
doi:10.1371/journal.ppat.1000250.g006
Figure 7. Factor H retains cofactor activity within the
Sbi:C3b:Factor H complex. Sbi-E, Sbi-I, Sbi-III/IV and Sbi-IV, and
the borrelial CRASP-1 were immobilized to the surface of a microtiter
plate. Factor H and C3b were added and following extensive washing
Factor I was applied. After 30 min incubation the mixture was harvested
and separated by SDS-PAGE. C3b degradation was analyzed by Western
blotting using a polyclonal C3 antiserum. The mobility of the a’ and b’
chain of C3b and the cleavage products a’68 and a’43 are indicated.
Factor H mediated cofactor activity is detected when the complex is
coupled to Sbi-E and Sbi-III/IV (lanes 1 and 3). The borrelial CRASP-1
protein and BSA were used as controls (lane 5 and 6). In the absence of
Factor H C3b remains intact (lanes 7 and 8).
doi:10.1371/journal.ppat.1000250.g007
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III and IV display an inhibitory effect. Compared to the other
staphylococcal complement regulators Efb and Ecb, Sbi does not
interfere with the activity of the classical pathway and did not
affect hemolysis mediated by the classical pathway (Figure 9D)
[29]. Thus Sbi forms a tripartite complex with the two human
complement proteins Factor H and C3, revealing- to our
knowledge- a novel mechanism for complement inhibition.
The inhibitory activity of Sbi is not restricted to human
complement as the protein also blocks complement of other
species i.e. mouse and guinea pig. Demonstrating that Sbi is a
staphylococcal virulence factor with a broader species range as
compared to the human specific inhibitor SCIN, which acts
specifically in the human system [29,34].
Sbi is a potent complement inhibitor, which interferes with the
hemolytic activity of human serum. In hemolytic assays with rabbit
erythrocytes Sbi used at 2 mg/ml ( = 0.3 mg) exclusively blocked
the alternative pathway whereas the classical and the lectin
pathways were unaffected (Figure 9D). However when used at
higher concentrations of 1000 mg/ml in an ELISA approach the
Sbi-III/IV fragment blocks all three activation pathways of human
complement but the Sbi-IV fragment is a specific inhibitor for the
alternative pathway (Burman et al. JBC in press). This activity
Figure 8. Characterization of the tripartite Sbi:Factor H:C3 complex. (A) Polyclonal Factor H antiserum blocks the formation of the Sbi:C3b:Factor
H complex. Sbi-E, Sbi-I, Sbi-III/IV and Sbi-IV were immobilized onto the surface of a microtiter plate and Factor H and C3b (upper panel) or Factor H, C3b
preincubated with polyclonal Factor H antiserum (lower panel) were added. After extensive washing the bound proteins were eluted, separated by SDS-
PAGE and Factor H was identified by Western blotting using polyclonal SCR 1–4 antiserum. Polyclonal Factor H antiserum inhibited formation of the
tripartite complex. CRASP-1 of B. burgdorferi and BSA were used as controls. (B) Formation of the tripartite Sbi-III/IV:C3d:Factor H complex was studied by
ELISA. In order to determine the minimal amount of C3d required for increased Factor H binding Sbi-III/IV was immobilized and Factor H in combination
with increasing amounts of C3d were added. Binding of Factor H was recorded. (C) Sbi-III/IV and BSA were immobilized, incubated with C3d and
increasing dilutions of C3d antiserum was added. After washing Factor H was added and binding was assayed. (D) Saturating concentrations of C3d
(0.2 mg) were added to immobilized Sbi-III/IV and BSA. Simultaneously Factor H was preincubated with increasing amounts of C3d and the proteinmixture
was added to the immobilized Sbi-III/IV:C3d complexes. Subsequently, Factor H binding was measured.
doi:10.1371/journal.ppat.1000250.g008
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differs from that of SCIN and its homologues SCIN-B and SCIN-
C, which affects all three complement pathways [29,34].
The staphylococcal Sbi protein is a multifunctional protein which
binds the complement effectors Factor H, FHR-1 and C3 and also
the processed forms C3b and C3d, as well as IgG and b2-
glycoprotein I. Thus Sbi mediates innate and adaptive immune
escape (i) by acquiring host complement inhibitors, which correlates
with the activation state of complement, (ii) by inhibiting complement
activation at the level of alternative pathway C3 convertase, (iii) by
binding and inactivation of IgG to avoid recognition by phagocytes,
and (iv) most likely by blocking C3dg binding to complement
receptor 2 (CR2) (Burman et al. JBC in press).
Materials and Methods
Bacterial strain and culture condition
S. aureus strain H591 (MSSA clinical isolate, UK) was grown at
37uC in tryptic soy broth (TSB, Sigma). The strain was
characterized for the presence of Sbi on DNA and protein level
(Figure S1A, S1B and S1C).
Adsorption experiments
Overnight cultures of S. aureus were diluted to OD600 = 0.2 in
TSB and incubated for about 1.5 h at 37uC to OD600 = 1.0
(approximately 1.26109 cfu). Cells (26109 cfu) were harvested by
centrifugation (6000 g, 8 min at room temperature), resuspended
in veronal buffered saline (GVB2+, Sigma) supplemented with
10 mM EDTA and incubated with either normal human serum
(NHS, diluted 1:10) or Factor H (100 mg/ml, Aventis Behring) for
1 h at 37uC with agitation. Subsequently, the cells were washed
four times with EDTA-GVB2+ and bound proteins were eluted
with SDS buffer (60 mM Tris-HCl, pH 6.8, 2% SDS, 25%
glycerine) for 5 min at 98uC. Wash and elute fractions were
separated by SDS-PAGE, transferred to a membrane and
analyzed by Western blotting using a polyclonal goat Factor H
antiserum (Merck) and horseradish peroxidase (hrp) coupled
rabbit anti goat antiserum (DAKO) for detection.
Cloning, expression and purification of recombinant Sbi
constructs
Recombinant fragments of the N-terminal region of Sbi (adjacent
to the poly-proline region) were engineered, expressed and purified
as described previously by (Burman et al. JBC in press). The
following Sbi constructs were used in this study: Sbi-E (amino acids
28–266) containing IgG-binding domains I and II and C3
interacting domains III and IV; Sbi-I (amino acids 42–94); Sbi-III-
IV (amino acids 150–266) and Sbi-IV (amino acids 197–266).
Expression of Factor H deletion mutants
The Factor H deletion mutants SCRs 1–7, SCRs 8–11, SCRs 11–
15, SCRs 15–18 and SCRs 19–20 were expressed in insect cells
infected with recombinant baculovirus as described earlier [39].
Briefly, Spodoptera frugiperda cells (Sf9) were grown at 28uC in
monolayer cultures in protein-free expression medium for insect cells
(BioWhittaker). Adherent Sf9 cells were infected with recombinant
virus using a multiplicity of infection of five. The culture supernatant
was harvested after 9 days and recombinant Factor H constructs were
purified by affinity chromatography using Ni-NTA-Agarose (Qiagen).
Antibody binding to Sbi-fragments
The complete extra cellular region, Sbi-E, and the extra cellular
deletion mutants Sbi-I, Sbi-III/IV, Sbi-IV, BSA (2 mg/ml each)
and Factor H (1 mg/ml) were immobilized onto a microtiter plate
for 2 h at room temperature. Unspecific binding sites were
blocked with 0.2% gelatine in DPBS (Lonza) over night at 4uC.
After extensive washing with PBSI (3.3 mM NaH2PO46H2O,
6.7 mM Na2HPO4, 145 mM NaCl, pH 7.2) supplemented with
0.05% Tween 20 a polyclonal rabbit SCR1–4 antiserum and the
two mABs B22 and C18 (all specific for Factor H) were added for
2 h at room temperature. Protein-antibody complexes were
detected using secondary horseradish peroxidase (HRP)-coupled
antiserum (e.g. rabbit anti goat-hrp (DAKO) rabbit anti mouse-
hrp (DAKO)) Respectively. All antibodies and antisera were used
at 1:1000 dilutions. The reaction was developed with 1,2-
phenylenediamine dihydrochloride (OPD, Dako) and the absor-
bency was measured at 490 nm.
Protein binding assay - CEWA
A combined ELISA and Western blot approach (CEWA) was
used to assay Factor H binding to Sbi-E and the deletion
constructs Sbi-I, Sbi-III/IV and Sbi-IV [36]. The proteins (10 mg/
ml) were immobilized onto a microtiter plate over night at 4uC.
After blocking with 0.2% gelatine in DPBS (Lonza) for 6 h at 4uC,
NHS (diluted 1:10), Factor H (5 mg/ml), a combination of Factor
H (5 mg/ml) and C3b (10 mg/ml, Merck), or Factor H (5 mg/ml)
and C3d (2,6 mg/ml, Merck) were added. For the C3-CEWA a
mixture of Factor H (5 mg/ml) and C3b or C3, iC3b, C3d (each
10 mg/ml, Merck), C3c, C3a (each 10 mg/ml, Comptech) were
added. Samples were incubated over night at 4uC. After extensive
washing protein complexes were removed with SDS buffer,
separated by SDS-PAGE and analyzed by Western blotting using
a polyclonal anti C3 antibody (Calbiochem) and anti-goat – hrp
(DAKO) was used for the detection of C3 and its degradation
products. For Factor H detection the mAB C18, which is specific
for SCR 20 of Factor H and rabbit anti mouse-hrp (DAKO) as
secondary antibody was used. As positive controls the borrelial
Factor H binding protein CRASP-1, and also the Factor H/FHR1
binding protein CRASP-5 (kindly provided by Dr. Peter Kraiczy
(University of Frankfurt a. M.) and by Prof. Dr. Reinhard Wallich
(University of Heidelberg)) and as negative control BSA were used.
Enzyme-linked immunosorband assay (ELISA)
The Factor H deletion constructs SCRs 1–7, SCRs 8–11, SCRs
11–15, SCRs 15–18, SCRs 19–20 and SCRs 15–20 were
Figure 9. Sbi is a complement inhibitor. (A) Alternative pathway-mediated hemolysis of rabbit erythrocytes was assayed in the presence of
increasing amounts of Sbi-E (columns 3–8) or Sbi-III/IV (columns 9–14). Hemolysis of rabbit erythrocytes with ddH2O is shown in column 1; hemolysis
in human serum is shown in column 2. (B) Hemolysis of rabbit erythrocytes following incubation in increasing concentrations of complement active
human serum in the absence (open squares) or the presence of Sbi-E (filled rhombi). (C) Lysis of rabbit erythrocytes in serum (30%) derived from the
indicated species; i.e. human, mouse, guinea pig, dog, goat and sheep. (D) Comparing the effect of Sbi on alternative pathway (AP)2, alternative,
classical and lectin pathway (AP+CP/LP)2, as well as classical and lectin pathway (CP/LP)-mediated hemolysis of human serum on rabbit erythrocytes.
Background lysis was subtracted for (A) and (C). NHS, normal human serum, DFB-HS, Factor B depleted human serum. (E) Sbi inhibits
opsonophagocytosis of S. aureus by THP-1 macrophage. Bacteria were incubated in 40% NHS in the presence or absence of Sbi for 20 min. Bacteria
were added to activated human THP1 macrophages and at the indicated times bacteria were recovered and the number of live bacteria was
quantitated. bacteria were plated on agar and the colony formation was determined (CFU).
doi:10.1371/journal.ppat.1000250.g009
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immobilized equimolar onto a microtiter plate over night at 4uC.
After blocking with Blocking Buffer I (AppliChem) for 2 h at 37uC,
a combination of C3b (5 mg/ml) and the Sbi deletion mutants Sbi-
E, Sbi-I and Sbi-III/IV used at equimolar amounts were added
and incubated for 1 h at room temperature. After excessive
washing bound Sbi deletion mutants were detected with polyclonal
Sbi antiserum (1:1000) and a secondary horseradish peroxidase-
coupled anti rabbit antiserum (1:1000, DAKO). To analyze the
complex formation, Sbi-III/IV (10 mg/ml) was coated and a
combination of Factor H (15 mg/ml) and C3, C3b, C3d, C3c
(Calbiochem) or C3a (15 mg/ml; Comptech) was added. The
complex was detected by polyclonal goat anti Factor H (1:1000)
and rabbit anti goat-hrp (1:1000, Dako).The reaction was
developed with 1,2-phenylenediamine dihydrochloride (OPD,
Dako) and the absorbency was measured at 490 nm.
Inhibition of protein binding with an antiserum
Sbi-E and the extra cellular deletion mutants Sbi-I, Sbi-III/IV,
Sbi-IV or CRASP-1, and BSA (10 mg/ml) were immobilized and
unspecific binding sites were blocked as described. Factor H
(5 mg/ml), polyclonal Factor H antiserum (diluted 1:100) and C3b
(10 mg/ml) were preincubated for 2 h at 4uC. Subsequently the
mixture was added to the immobilized proteins and incubated
over night at 4uC. After extensive washing protein complexes were
removed from the well with SDS buffer, separated by SDS-PAGE
and analyzed by Western blotting with the polyclonal rabbit
SCR1–4 antiserum and swine anti rabbit-hrp (DAKO) as
secondary antibody.
Complement cofactor assay
For determining the regulatory activity of Sbi-bound Factor H,
the regulator (3 mg/ml) together with C3b (6 mg/ml) or C3b
(6 mg/ml) alone were added to immobilized Sbi-E, Sbi-I, Sbi-III/
IV, Sbi-IV, CRASP-1, or BSA (10 mg/ml) incubated over night at
4uC. After extensive washing Factor I (0.8 mg) was added and the
mixture was incubated for 30 min at 37uC. C3b conversion to
inactive C3b (iC3b) was detected after separating the protein
solution by SDS-PAGE with Western blot analysis using a
polyclonal goat C3 antiserum (1:1000, Merck) and rabbit anti
goat-hrp (DAKO) as secondary antibody.
SDS-PAGE and Western blot analysis
Samples were separated by SDS-PAGE using 10% and 12% gels.
After the transfer of the proteins onto nitrocellulose membranes by
semi-dry blotting [40], the membranes were blocked with 5% (w/v)
dried milk in PBSI for 30 min at room temperature and incubated
with the indicated primary antibodies over night at 4uC. Antibodies
were diluted in 2.5% (w/v) dried milk in PBSI. The proteins were
detected by ECL using appropriate secondary antisera that was
coupled with horseradish peroxidase.
Surface plasmon resonance studies
Protein-protein interactions were analyzed by the surface
plasmon resonance technique using a Biacore 3000 instrument
(Biacore AB) as described [41]. Briefly, the staphylococcal proteins
Sbi-E, Sbi-I, Sbi-III/IV or human C3d were coupled to the
surface of the flow cells of the sensor chip via a standard amine-
coupling procedure (carboxylated dextran chip CM5, Biacore AB)
until about 2000 resonance units were reached. A control cell was
prepared under identical conditions that lacked a protein. Sbi-E,
Factor H, C3, C3b or C3d were diluted in DPBS (Lonza), adjusted
to equal molarities and injected with a flow rate of 5 ml/min at
25uC. Alternatively, Ni2+ and Sbi-E was loaded to a NTA-chip,
and C3d followed by Factor H were injected at equimolar
amounts. Each interaction was analyzed at least three times.
Hemolytic assays
In order to analyze the complement regulatory effect of Sbi,
hemolytic assays were performed using rabbit erythrocytes (rE,
Rockland). Rabbit erythrocytes represent activator surfaces for
human serum and lyse due to MAC formation. Thus the
complement activity correlates directly with the erythrocyte lysis
as monitored by the increase in absorbance. Following preincu-
bation of NHS with Sbi-E or Sbi-III/IV for 30 min at 37uC,
56106 rE were added (150 ml total volume) and further incubated
for 30 min at 37uC. After centrifugation (2 min, 5000 rpm) the
absorbency of the supernatant was measured at 414 nm. NHS,
Sbi-E and Sbi-III/IV were used at the indicated concentrations.
Samples were diluted in HEPES buffer (20 mM HEPES, 144 mM
NaCl, 7 mM MgCl2, 10 mM EGTA, 1% BSA, pH 7.4). The
effect of Sbi on different animal sera (Innovative Research) was
assayed using 30% animal serum and 2 mg (13 mg/ml) Sbi-E.
In order to analyze and distinguish between the alternative and
the classical/lectin pathway complement activation was pursued in
different buffers. Alternative pathway activity was measured in
EGTA-HEPES buffer. Activation of all three pathways was assayed
in Ca2+-HEPES buffer (20 mM HEPES, 144 mM NaCl, 5 mM
CaCl2, 2,5 mM MgCl2, pH 7.4). The effect of the classical and the
lectin pathway was assayed in Factor B deficient serum (Comple-
ment Technology Inc.) and the Ca2+-HEPES buffer. All three
approaches (AP, AP+CP/LP and CP/LP) were analyzed in the
presence of none, 0.3 mg (2 mg/ml) and 1.0 mg (6,7 mg/ml) Sbi-E.
S.aureus survival assay
Bacteria S. aureus strain H591 (66104) were incubated in 40%
NHS supplemented with HEPES EGTA in presence or absence of
Sbi-E for 15 min at 37uC. Samples were added to 86105 PMA
primed THP-1 macrophages in antibiotic free RPMI-1640
resulting in a final Sbi-E concentration of 2 mg/ml. THP-1 cells
incubated without S. aureus were used as negative control. After
shaking 20 ml sample were plated hourly. Plates were incubated
overnight and colonies were counted.
Accession codes
National Centre for Biotechnology Information (www.ncbi.nlm.
nih.gov): Homo sapiens complement factor H (CFH), gi|62739185|
ref|NM_000186.2|[62739185]; Homo sapiens complement factor
H-related 1 (CFHR1), NM_002113.2 GI:118442838; Homo sapiens
complement component 3 (C3), NM_000064.2 GI:115298677;
immunoglobulin G-binding protein Sbi [Staphylococcus aureus
subsp. aureus str. Newman], YP_001333351.1 GI:151222529.
Supporting Information
Figure S1 Characterization of H591. S. aureus H591 were grown
overnight on LB-Agar. Individual colonies were picked and lysed
in 50 ml dH2O for 10 min at 96 uC. A standard PCR was
performed using Sbi specific Primers (Sbi-fw GCGAGTGAAAA-
CACGCAACA, Sbi-rev CGCCACTTTCTTTTCAGCAT).
Samples were analyzed on a 1% agarose-gel. To analyze the
existence and location of the Sbi protein for S. aureus H591, a 20
ml overnight culture was separated. The supernatant was
concentrated 10-fold using the Centricon-Plus-20 (Millipore)
concentrators. The resulting cell-pellet was disintegrated by bead
beating (Mini-BeadBeater-1, BioSpec). The extract was centri-
fuged at 13200 rpm for 10 min. The supernatant containing
soluble proteins was defined as ‘‘cytoplasm’’ fraction. The residual
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pellet was washed with 1x PBS, separated from the glass beads and
defined as ‘‘cell-wall’’ fraction. Samples were separated SDS-Page
followed by Western blotting. Sbi was detected using specific anti
Sbi F(ab’)2 Fragments generated with the F(ab’)2 Preparation Kit
(Pierce). Anti-rabbit F(ab’)2 -hrp (Santa Cruz Biotechnology) was
used as secondary antibody. Protein A (Sigma) was used as control.
Protein A (1 mg) and Sbi-E (1 mg) were separated on SDS page in
triplicate and Western blotted. The blot was cut in three parts and
proteins were detected using following antibody combinations:
anti-Sbi F(ab’)2 and goat anti-rabbit F(ab’)2 - hrp, rabbit anti-goat
- hrp, rabbit Sbi antiserum and goat anti-rabbit F(ab’)2 - hrp. (A) S.
aureus strain H591 expresse Sbi. Sbi was detected in the
cytoplasmic and cell-wall fraction and a truncated form in the
concentrated supernatant. Sbi was detected using polyclonal
rabbit anti-Sbi F(ab’)2 and goat anti-rabbit F(ab’)2 - hrp as
secondary antibody. (B) FACS analysis confirmed the presence of
Sbi on surface of S. aureus. Anti-Sbi F(ab’)2 and Alexa488 coupled
anti-rabbit F(ab’)2 was used for detection. An unspecific Alexa488
coupled rabbit F(ab’)2 and the secondary F(ab’)2 was used as
negative controls (C) S. aureus H591 carries the Sbi encoding gene.
The sbi-gene was amplified using specific primers. (D) The sbi-
gene of four separate colonies was sequenced and aligned to the
sbi-gene of S. aureus Newman strain. Six sequence variations were
detected and one affects the protein-sequence V169I. (E) Anti-Sbi
F(ab’)2 shows no crossreactivity with Protein A (SpA). SpA and
Sbi-E was separated on SDS page in triplicate and analyzed by
Western blotting. Proteins were detected using following antibody
combinations: anti-Sbi F(ab’)2 and a secondary goat anti-rabbit
F(ab’)2- hrp (Lane 1 and 2), rabbit anti-goat - hrp (Lane 3 and 4),
Sbi antiserum and the secondary anti-rabbit F(ab’)2 - hrp (Lane 5
and 6).
Found at: doi:10.1371/journal.ppat.1000250.s001 (0.26 MB PDF)
Figure S2 1:1 model (langmuir). (A) Concentration-dependent
interaction of the C3d to immobilized Sbi-E was recorded in real
time by surface plasmon resonance. A kinetic model shows that
this profile does not fit a 1:1 langmuir interaction. Solid lanes
representing the calculated data do not match the experimental
data. (B) The experimental data fit a theoretical 2:1 interaction
much better, as experimental and fitted data show a good match
and rather low deviation. The residual blots (C,D) show the
difference between the experimental and the fitted data for each
curve. This presentation reveals systematic deviations between the
experimental and the calculated data. (C) The curves for a 1:1
interaction show a large variation. (D) The 2:1 interaction model
show a much better fit between the experimental and fitted data.
The deviation is very low. For a perfect fit, the scatter in the
residual plot is a measure of the noise in the signal. Normally the
noise levels are in */- 2 RU.
Found at: doi:10.1371/journal.ppat.1000250.s002 (0.29 MB PDF)
Figure S3 Immobilization of Sbi I onto the surface of the sensor
chip was followed. (A) Upon sequential injection of the protein, a
bulk effect is observed. When the probe was washed, an increase in
the base line is detected which demonstrates immobilization of the
ligand. This step was repeated four times until a level of
immobilization of approximately 1,800 RU was detected (D). (B)
An unspecific mouse IgG preparation binds to immobilized Sbi-I,
thus demonstrating that immobilized Sbi-I is accessible and binds
ligands. Similarly, IgG did also bind to the immobilized IgG
binding Sbi-E. No binding was observed for the NON IgG binding
Sbi-III/IV fragment. This profile represents the unspecific bulk
effect. However, when binding of C3d was analysed, the
immobilized Sbi-III/IV fragment showed binding (compare
Figure 5).
Found at: doi:10.1371/journal.ppat.1000250.s003 (0.01 MB PDF)
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